{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T15:07:18Z","timestamp":1794236838513,"version":"4.9.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T00:00:00Z","timestamp":1708128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T00:00:00Z","timestamp":1708128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"crossref","award":["BK20220723"],"award-info":[{"award-number":["BK20220723"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273066"],"award-info":[{"award-number":["82273066"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>circular RNAs (circRNAs) have been reported to exert important effects in the progression of numerous cancers. However, the functions of circRNAs in intrahepatic cholangiocarcinoma (ICC) are still unclear.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>circPCNXL2 (has_circ_0016956) were identified in paired ICC by circRNA microarray. Then, we assessed the biological functions of circPCNXL2 by CCK8, EdU, clone formation, transwell, wound healing assays, and xenograft models. RNA pull-down, mass spectrometry, and RNA immunoprecipitation (RIP) were applied to explore the interaction between cirrcPCNXL2 and serine-threonine kinase receptor-associated protein (STRAP). RNA pull-down, RIP and luciferase reporter assays were used to investigate the sponge functions of circPCNXL2. In the end, we explore the effects of circPCNXL2 and trametinib (a MEK1\/2 inhibitor) in vivo.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>circPCNXL2 was upregulated in ICC tissues and cell lines, which promoted the proliferation and metastasis of ICC in vitro and in vivo. In terms of the mechanisms, circPCNXL2 could directly bind to STRAP and induce the interaction between STRAP and MEK1\/2, resulting in the tumor promotion in ICC by activation of ERK\/MAPK pathways. Besides, circPCNXL2 could regulate the expression of SRSF1 by sponging miR-766-3p and subsequently facilitated the growth of ICC. Finally, circPCNXL2 could partially inhibit the anti-tumor activity of trametinib in vivo.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>circPCNXL2 played a crucial role in the progression of ICC by interacting with STRAP to activate the ERK signaling pathway, as well as by modulating the miR-766-3p\/SRSF1 axis. These findings suggest that circPCNXL2 may be a promising biomarker and therapeutic target for ICC.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12943-024-01950-y","type":"journal-article","created":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T03:02:07Z","timestamp":1708138927000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["CircPCNXL2 promotes tumor growth and metastasis by interacting with STRAP to regulate ERK signaling in intrahepatic cholangiocarcinoma"],"prefix":"10.1186","volume":"23","author":[{"given":"Shuochen","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yirui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianlin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuangheng","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilong","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jifei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wangjie","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaodong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yananlan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changxian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangcheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,17]]},"reference":[{"issue":"1","key":"1950_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, et al. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7\u201333.","journal-title":"CA Cancer J Clin"},{"key":"1950_CR2","doi-asserted-by":"crossref","unstructured":"Jarnagin WR et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg, 2001. 234(4): p. 507\u2009\u2013\u200917; discussion 517-9.","DOI":"10.1097\/00000658-200110000-00010"},{"issue":"2","key":"1950_CR3","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/nrclinonc.2017.157","volume":"15","author":"S Rizvi","year":"2018","unstructured":"Rizvi S, et al. Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018;15(2):95\u2013111.","journal-title":"Nat Rev Clin Oncol"},{"key":"1950_CR4","doi-asserted-by":"crossref","unstructured":"Nemeth K et al. Non-coding RNAs in disease: from mechanisms to therapeutics. Nat Rev Genet, 2023.","DOI":"10.1038\/s41576-023-00662-1"},{"issue":"7644","key":"1950_CR5","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/543183a","volume":"543","author":"K Adelman","year":"2017","unstructured":"Adelman K, Egan E. Non-coding RNA: more uses for genomic junk. Nature. 2017;543(7644):183\u20135.","journal-title":"Nature"},{"key":"1950_CR6","doi-asserted-by":"crossref","unstructured":"Piwecka M et al. Loss of a mammalian circular RNA locus causes miRNA deregulation and affects brain function. Science, 2017. 357(6357).","DOI":"10.1126\/science.aam8526"},{"issue":"13","key":"1950_CR7","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1016\/j.cell.2022.06.001","volume":"185","author":"CX Liu","year":"2022","unstructured":"Liu CX, Chen LL. Circular RNAs: characterization, cellular roles, and applications. Cell. 2022;185(13):2390.","journal-title":"Cell"},{"issue":"8","key":"1950_CR8","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.7150\/thno.42174","volume":"10","author":"A Huang","year":"2020","unstructured":"Huang A, et al. Circular RNA-protein interactions: functions, mechanisms, and identification. Theranostics. 2020;10(8):3503\u201317.","journal-title":"Theranostics"},{"issue":"1","key":"1950_CR9","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12943-020-01286-3","volume":"19","author":"WY Zhou","year":"2020","unstructured":"Zhou WY, et al. Circular RNA: metabolism, functions and interactions with proteins. Mol Cancer. 2020;19(1):172.","journal-title":"Mol Cancer"},{"key":"1950_CR10","doi-asserted-by":"publisher","first-page":"215980","DOI":"10.1016\/j.canlet.2022.215980","volume":"553","author":"W Liao","year":"2023","unstructured":"Liao W, et al. Circular RNAs in cholangiocarcinoma. Cancer Lett. 2023;553:215980.","journal-title":"Cancer Lett"},{"key":"1950_CR11","doi-asserted-by":"crossref","unstructured":"Lee S, Rauch J, Kolch W. Targeting MAPK signaling in Cancer: mechanisms of Drug Resistance and Sensitivity. Int J Mol Sci, 2020. 21(3).","DOI":"10.3390\/ijms21031102"},{"issue":"4","key":"1950_CR12","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.bbadis.2009.12.009","volume":"1802","author":"EK Kim","year":"2010","unstructured":"Kim EK, Choi EJ. Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta. 2010;1802(4):396\u2013405.","journal-title":"Biochim Biophys Acta"},{"issue":"9992","key":"1950_CR13","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","volume":"386","author":"GV Long","year":"2015","unstructured":"Long GV, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386(9992):444\u201351.","journal-title":"Lancet"},{"issue":"12","key":"1950_CR14","doi-asserted-by":"publisher","first-page":"6156","DOI":"10.1158\/0008-5472.CAN-05-3261","volume":"66","author":"SK Halder","year":"2006","unstructured":"Halder SK, et al. Oncogenic function of a novel WD-domain protein, STRAP, in human carcinogenesis. Cancer Res. 2006;66(12):6156\u201366.","journal-title":"Cancer Res"},{"issue":"1","key":"1950_CR15","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1053\/j.gastro.2021.09.010","volume":"162","author":"T Vu","year":"2022","unstructured":"Vu T, et al. Serine-threonine kinase receptor-Associated protein is a critical mediator of APC mutation-Induced Intestinal Tumorigenesis through a feed-Forward mechanism. Gastroenterology. 2022;162(1):193\u2013208.","journal-title":"Gastroenterology"},{"issue":"2","key":"1950_CR16","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1158\/1541-7786.MCR-18-0054","volume":"17","author":"W Wang","year":"2019","unstructured":"Wang W, et al. Oncogenic STRAP supports Hepatocellular Carcinoma Growth by enhancing Wnt\/beta-Catenin signaling. Mol Cancer Res. 2019;17(2):521\u201331.","journal-title":"Mol Cancer Res"},{"issue":"12","key":"1950_CR17","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1111\/bph.16024","volume":"180","author":"Z Zhang","year":"2023","unstructured":"Zhang Z, et al. Squalene epoxidase promotes hepatocellular carcinoma development by activating STRAP transcription and TGF-beta\/SMAD signalling. Br J Pharmacol. 2023;180(12):1562\u201381.","journal-title":"Br J Pharmacol"},{"issue":"52","key":"1950_CR18","doi-asserted-by":"publisher","first-page":"34671","DOI":"10.1074\/jbc.273.52.34671","volume":"273","author":"PK Datta","year":"1998","unstructured":"Datta PK, et al. Identification of STRAP, a novel WD domain protein in transforming growth factor-beta signaling. J Biol Chem. 1998;273(52):34671\u20134.","journal-title":"J Biol Chem"},{"issue":"1","key":"1950_CR19","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jhep.2021.08.027","volume":"76","author":"Q Chen","year":"2022","unstructured":"Chen Q, et al. Circular RNA ACTN4 promotes intrahepatic cholangiocarcinoma progression by recruiting YBX1 to initiate FZD7 transcription. J Hepatol. 2022;76(1):135\u201347.","journal-title":"J Hepatol"},{"issue":"12","key":"1950_CR20","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of Fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550.","journal-title":"Genome Biol"},{"issue":"22","key":"1950_CR21","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1038\/sj.onc.1210421","volume":"26","author":"AS Dhillon","year":"2007","unstructured":"Dhillon AS, et al. MAP kinase signalling pathways in cancer. Oncogene. 2007;26(22):3279\u201390.","journal-title":"Oncogene"},{"key":"1950_CR22","doi-asserted-by":"publisher","first-page":"p6218353","DOI":"10.1155\/2017\/6218353","volume":"2017","author":"L Bolha","year":"2017","unstructured":"Bolha L, Ravnik-Glavac M, Glavac D. Circular RNAs: Biogenesis, function, and a role as possible Cancer biomarkers. Int J Genomics. 2017;2017:p6218353.","journal-title":"Int J Genomics"},{"issue":"7441","key":"1950_CR23","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/nature11993","volume":"495","author":"TB Hansen","year":"2013","unstructured":"Hansen TB, et al. Natural RNA circles function as efficient microRNA sponges. Nature. 2013;495(7441):384\u20138.","journal-title":"Nature"},{"key":"1950_CR24","doi-asserted-by":"publisher","first-page":"34985","DOI":"10.1038\/srep34985","volume":"6","author":"X Chen","year":"2016","unstructured":"Chen X, et al. circRNADb: a comprehensive database for human circular RNAs with protein-coding annotations. Sci Rep. 2016;6:34985.","journal-title":"Sci Rep"},{"key":"1950_CR25","doi-asserted-by":"crossref","unstructured":"McGeary SE et al. The biochemical basis of microRNA targeting efficacy. Science, 2019. 366(6472).","DOI":"10.1126\/science.aav1741"},{"key":"1950_CR26","doi-asserted-by":"crossref","unstructured":"Agarwal V et al. Predicting effective microRNA target sites in mammalian mRNAs. Elife, 2015. 4.","DOI":"10.7554\/eLife.05005"},{"issue":"10","key":"1950_CR27","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1261\/rna.5248604","volume":"10","author":"M Rehmsmeier","year":"2004","unstructured":"Rehmsmeier M, et al. Fast and effective prediction of microRNA\/target duplexes. RNA. 2004;10(10):1507\u201317.","journal-title":"RNA"},{"issue":"9","key":"1950_CR28","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1002\/ijc.30853","volume":"141","author":"C Chen","year":"2017","unstructured":"Chen C, et al. DNA-methylation-mediated repression of mir-766-3p promotes cell proliferation via targeting SF2 expression in renal cell carcinoma. Int J Cancer. 2017;141(9):1867\u201378.","journal-title":"Int J Cancer"},{"issue":"W1","key":"1950_CR29","doi-asserted-by":"publisher","first-page":"W98","DOI":"10.1093\/nar\/gkx247","volume":"45","author":"Z Tang","year":"2017","unstructured":"Tang Z, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98\u2013W102.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"1950_CR30","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41389-023-00447-5","volume":"12","author":"Y Xu","year":"2023","unstructured":"Xu Y, et al. HLTF promotes hepatocellular carcinoma progression by enhancing SRSF1 stability and activating ERK\/MAPK pathway. Oncogenesis. 2023;12(1):2.","journal-title":"Oncogenesis"},{"issue":"24","key":"1950_CR31","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1038\/s41388-023-02710-w","volume":"42","author":"Z Feng","year":"2023","unstructured":"Feng Z, et al. RNF125 attenuates hepatocellular carcinoma progression by downregulating SRSF1-ERK pathway. Oncogene. 2023;42(24):2017\u201330.","journal-title":"Oncogene"},{"issue":"1","key":"1950_CR32","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jtho.2021.08.011","volume":"17","author":"D Planchard","year":"2022","unstructured":"Planchard D, et al. Phase 2 study of Dabrafenib Plus Trametinib in patients with BRAF V600E-Mutant metastatic NSCLC: updated 5-Year Survival Rates and genomic analysis. J Thorac Oncol. 2022;17(1):103\u201315.","journal-title":"J Thorac Oncol"},{"key":"1950_CR33","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.ejca.2022.04.018","volume":"170","author":"C Garbe","year":"2022","unstructured":"Garbe C, et al. European consensus-based interdisciplinary guideline for melanoma. Part 2: treatment - update 2022. Eur J Cancer. 2022;170:256\u201384.","journal-title":"Eur J Cancer"},{"issue":"11","key":"1950_CR34","doi-asserted-by":"publisher","first-page":"e516","DOI":"10.1016\/S1470-2045(20)30625-2","volume":"21","author":"V Subbiah","year":"2020","unstructured":"Subbiah V, et al. Dabrafenib plus Trametinib in patients with BRAF(V600E)-mutated biliary tract cancer - authors\u2019 reply. Lancet Oncol. 2020;21(11):e516.","journal-title":"Lancet Oncol"},{"issue":"2","key":"1950_CR35","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jhep.2021.02.032","volume":"75","author":"G Cristinziano","year":"2021","unstructured":"Cristinziano G, et al. FGFR2 fusion proteins drive oncogenic transformation of mouse liver organoids towards cholangiocarcinoma. J Hepatol. 2021;75(2):351\u201362.","journal-title":"J Hepatol"},{"issue":"3","key":"1950_CR36","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1016\/j.jcmgh.2021.05.011","volume":"12","author":"S Wabitsch","year":"2021","unstructured":"Wabitsch S, et al. Anti-PD-1 in Combination with Trametinib suppresses Tumor Growth and improves survival of Intrahepatic Cholangiocarcinoma in mice. Cell Mol Gastroenterol Hepatol. 2021;12(3):1166\u201378.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"2","key":"1950_CR37","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3390\/jmp3020009","volume":"3","author":"A Barbato","year":"2022","unstructured":"Barbato A, et al. Micro-RNA in Cholangiocarcinoma: implications for diagnosis, prognosis, and Therapy. J Mol Pathol. 2022;3(2):88\u2013103.","journal-title":"J Mol Pathol"},{"issue":"8","key":"1950_CR38","doi-asserted-by":"publisher","first-page":"173","DOI":"10.31083\/j.fbl2808173","volume":"28","author":"J Li","year":"2023","unstructured":"Li J, et al. Non-coding RNA in Cholangiocarcinoma: an update. Front Biosci (Landmark Ed). 2023;28(8):173.","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"1","key":"1950_CR39","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1186\/s13046-021-02095-2","volume":"40","author":"YP Xu","year":"2021","unstructured":"Xu YP, et al. circHMGCS1-016 reshapes immune environment by sponging mir-1236-3p to regulate CD73 and GAL-8 expression in intrahepatic cholangiocarcinoma. J Exp Clin Cancer Res. 2021;40(1):290.","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"1950_CR40","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1002\/hep.31493","volume":"73","author":"Y Xu","year":"2021","unstructured":"Xu Y, et al. A circular RNA, Cholangiocarcinoma-Associated Circular RNA 1, contributes to Cholangiocarcinoma Progression, induces angiogenesis, and disrupts vascular endothelial barriers. Hepatology. 2021;73(4):1419\u201335.","journal-title":"Hepatology"},{"issue":"3","key":"1950_CR41","first-page":"1997","volume":"19","author":"YJ Guo","year":"2020","unstructured":"Guo YJ, et al. ERK\/MAPK signalling pathway and tumorigenesis. Exp Ther Med. 2020;19(3):1997\u20132007.","journal-title":"Exp Ther Med"},{"issue":"2","key":"1950_CR42","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1038\/bjc.2017.418","volume":"118","author":"RT Shroff","year":"2018","unstructured":"Shroff RT, et al. The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma. Br J Cancer. 2018;118(2):e2.","journal-title":"Br J Cancer"},{"issue":"1","key":"1950_CR43","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12943-021-01482-9","volume":"21","author":"J Du","year":"2022","unstructured":"Du J, et al. CircNFIB inhibits tumor growth and metastasis through suppressing MEK1\/ERK signaling in intrahepatic cholangiocarcinoma. Mol Cancer. 2022;21(1):18.","journal-title":"Mol Cancer"},{"issue":"1","key":"1950_CR44","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41419-022-05540-y","volume":"14","author":"X Yu","year":"2023","unstructured":"Yu X, et al. CircRNA MBOAT2 promotes intrahepatic cholangiocarcinoma progression and lipid metabolism reprogramming by stabilizing PTBP1 to facilitate FASN mRNA cytoplasmic export. Cell Death Dis. 2023;14(1):20.","journal-title":"Cell Death Dis"},{"key":"1950_CR45","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.ebiom.2018.07.036","volume":"34","author":"Z Zhang","year":"2018","unstructured":"Zhang Z, Yang T, Xiao J. Circular RNAs: promising biomarkers for Human diseases. EBioMedicine. 2018;34:267\u201374.","journal-title":"EBioMedicine"},{"issue":"1","key":"1950_CR46","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13046-020-01791-9","volume":"40","author":"J Cao","year":"2021","unstructured":"Cao J, et al. Circular RNA circLMO7 acts as a microRNA-30a-3p sponge to promote gastric cancer progression via the WNT2\/beta-catenin pathway. J Exp Clin Cancer Res. 2021;40(1):6.","journal-title":"J Exp Clin Cancer Res"},{"issue":"14","key":"1950_CR47","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273\u201381.","journal-title":"N Engl J Med"},{"issue":"8","key":"1950_CR48","doi-asserted-by":"publisher","first-page":"e371","DOI":"10.1016\/S1470-2045(20)30394-6","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, Pandya SS, Zhu AX. Ivosidenib for advanced IDH1-mutant cholangiocarcinoma - authors\u2019 reply. Lancet Oncol. 2020;21(8):e371.","journal-title":"Lancet Oncol"},{"issue":"8","key":"1950_CR49","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1111\/liv.15641","volume":"43","author":"M Rimini","year":"2023","unstructured":"Rimini M, et al. Durvalumab plus Gemcitabine and cisplatin in advanced biliary tract cancer: an early exploratory analysis of real-world data. Liver Int. 2023;43(8):1803\u201312.","journal-title":"Liver Int"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-024-01950-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-024-01950-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-024-01950-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T04:27:28Z","timestamp":1708144048000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-024-01950-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,17]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1950"],"URL":"https:\/\/doi.org\/10.1186\/s12943-024-01950-y","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,17]]},"assertion":[{"value":"22 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of the First Affiliated Hospital of Nanjing Medical University. The patients\u2019 informed consent was obtained according to regional regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"35"}}